Stock to Watch: Lantern Pharma Using AI to Revolutionize Cancer Treatment
Lantern Pharma (Nasdaq: LTRN), a clinical-stage biopharmaceutical company, has announced a collaboration with Bielefeld University to develop high therapeutic and antitumor potential ADCs (antibody-drug conjugates) using its RADR® AI platform. This collaboration aims to synthesize and evaluate novel ADCs linked to cryptophycins, an antitumor agent that inhibits tumor growth.
ADCs developed through this collaboration could provide new therapeutic options for patients with advanced cancers and the use of AI technology in ADC development could revolutionize the field and lead to more personalized and effective cancer treatments.
Lantern’s RADR® platform will be leveraged to select and advance cryptophycin-ADCs towards the clinic with better targeting and therapeutic efficacy. This approach has the potential to de-risk the ADC drug development process and enhance the creation of effective and targeted ADCs.
Lantern Pharma’s long-term strategy is to launch multiple ADC products and its partnership with Bielefeld University has the potential to tap into the rapidly growing global ADC market valued at over $4 billion.
The use of AI technology in drug development has the potential to transform the field of cancer treatment and provide new hope for patients with advanced cancers.
